Anvisa approves second generic semaglutide in Brazil

Brazilian health regulator Anvisa has authorized the production of a second generic version of semaglutide, manufactured by Germed Farmacêutica. The entry of this competitor is expected to reduce market prices by at least 35%, though the final retail pricing remains unconfirmed.